Validation of microarray data using qRT-PCR.

***<p>p<0.001; **p<0.01; *p<0.05; ^NS – not significant.</p><p>All genes abbreviations are explained in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0050054#pone-0050054-t002" target="_blank">Table 2</a>.</p

Differentially expressed genes common to both analyses: admission versus control and discharge versus control.

<p>Differentially expressed genes common to both analyses: admission versus control and discharge versus control.</p

Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus control.

<p>Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus control.</p

Expression data from microarray experiments for chosen genes.

<p>The y-axis represents the log2 normalized intensity of the gene and the x-axis represents analyzed groups. The line inside the box and whiskers represents the median of the samples in a group. Points present relative expression levels in individual patients at admission (blue), at discharge (green), 6 month after MI (violet) and from control group (red). Numbers indicate the coded identity of a particular patient. SOCS3– suppressor of cytokine signaling 3; ST14– MT-SP1/matriptase; AQP 9– aquaporin 9; MYBL1– v-myb myeloblastosis viral oncogene homolog (avian)-like 1; STAB1– stabilin 1; ASGR2– asialoglycoprotein receptor 2.</p

Major characteristics of the study and control groups.

*<p>Mean ± Standard Deviation.</p>**<p>number (%);</p><p>NA – not applicable.</p

Top canonical pathways associated with acute phase of STEMI.

<p>Ingenuity Pathway Analysis of gene sets differentially expressed on the first day of myocardial infarction versus 6 months after MI or versus control group was performed. Functional categories are represented on the x-axis. The significance is expressed as the negative exponent on the p-value calculated for each function on the y-axis of the diagram, increasing with bar height.</p

Nile Red staining of yeast lipid particles.

<p>Visualization of membranes composed of glycerophospholipids (red emission) and neutral lipids, triacyglycerols and steryl esters, in lipid particles (green emission). Cells were cultured overnight. The media were then supplemented with either 100 µM simvastatin or buffer and the cells were further grown with shaking for two hours at 30°C. To localize neutral lipids and glycerophospholipids in yeast cells, Nile Red staining was performed. Horizontal panels: upper glycrophospholipids at 543 nm excitation and 610 nm emission, middle neutral lipids at 488 nm excitation and 515/530 nm emission, lower merge of above panels. Vertical panels: B cells cultivated in buffer, S cells incubated for 2 h in buffer with simvastatin.</p

Two dimensional chromatography of glycerophospholipids.

<p>The levels of all major glycerophospholipids were diminished by treatment with simvastatin. Panels: 1, 3, 5 glycerophospholipids from cells harbouring the wild-type yeast, or the wild-type or mutated <i>hHMGR</i> gene, respectively. Panels 2, 4, 6 glycerophospholipids from simvastatin treated cells harbouring the wild-type yeast, or the wild-type or mutated <i>hHMGR</i> gene, respectively. Abbreviations: PC phosphtidylcholine, PE phosphtidylethanolamine, PS phosphatidylserine, PI phosphtidylinositol, PA phosphtidic acid, LP lysoglycerophospholipid, FA fatty acid, NL neutral lipids.</p

Decrease in sterols and squalene after simvastatin treatment.

<p>Lipids extracted from yeast cells were subjected to alkaline hydrolysis, purified and analysed by GC/MS.</p><p>Wt, wild-type yeast; H, yeast harbouring wild-type <i>hHMGR</i> gene; h, yeast harbouring the mutated <i>hHMGR</i> gene.</p

TLC analysis of complex lipids.

<p>Effect of simvastatin treatment on glycerophospholipids, apparently not connected with mevalonate pathway. Lanes 1, 3, 5 lipids from cells harbouring the wild-type yeast, or the wild-type or mutated <i>hHMGR</i> gene, respectively. Lanes 2, 4, 6 lipids from cells treated with simvastatin harbouring the wild-type yeast, or the wild-type or mutated <i>hHMGR</i> gene, respectively. Abbreviations: SQ squalene, SM simvastatin metabolites, PE phosphtidylethanolamine, GPL glycerophospholipids, SF sphingomyeline.</p